GE Healthcare of Chalfont St. Giles, U.K., said that a head-to-head taste test of oral contrast agents found a significantly greater preference for its Omnipaque agent (iohexol) compared to Covidien's Gastroview (diluted diatrizoate sodium).
The study, published in the November issue of the American Journal of Roentgenology, also found no significant differences between the agents in terms of side effects or bowel opacification, according to lead author Michelle McNamara, MD, of the University of Alabama at Birmingham.
The prospective, double-blind study included 300 adult patients.
Related Reading
GE to continue health academy support, November 9, 2010
GE wins 7T Wis. MRI contract, November 5, 2010
GE inks consulting deal with West Physics, November 4, 2010
GE shows MRI options, software at ASTRO, November 3, 2010
Study: Patients prefer iohexol contrast taste, March 3, 2010
Copyright © 2010 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
